Literature DB >> 19810172

An evaluation of the activity of cephalosporins against Pseudomonas aeruginosa.

A Bauernfeind1.   

Abstract

We investigated the in-vitro activity of 14 antibiotics against 200 distinct isolates of Pseudomonas aeruginosa obtained from intensive care patients. Ceftazidime was the most active beta-lactam and 16 mg/l inhibited 88% of the strains. Of 55 two-drug combinations, ceftazidime plus tobramycin was the most effective and 98.5% of strains were sensitive. Synergism between these two drugs was demonstrated for 12 of the 23 strains tested. Ceftazidime-inactivating enzymes may be induced in Ps. aeruginosa by cefoxitin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 19810172     DOI: 10.1093/jac/8.suppl_b.111

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Therapy of pseudomonal infections.

Authors:  A Kumar
Journal:  Indian J Pediatr       Date:  1987 Jul-Aug       Impact factor: 1.967

2.  Antibacterial activity of temocillin in combination with other beta-lactam antibiotics.

Authors:  L Verbist; J Verhaegen
Journal:  Drugs       Date:  1985       Impact factor: 9.546

3.  Treatment of Pseudomonas aeruginosa septicemia in neutropenic patients with ceftazidime.

Authors:  B E de Pauw; T de Witte; J T Janssen; C Haanen
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

4.  The current state of cephalosporin antibiotics: microbiological aspects.

Authors:  H Knothe; G A Dette
Journal:  Infection       Date:  1983       Impact factor: 3.553

Review 5.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 6.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.